Regenerative medicine company, Regeneus (ASX: RGS), has received a notice of intention to grant a European patent covering the use of Progenza by the European Patent Office.
Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of osteoarthritis and other musculoskeletal diseases. It also has the potential to be used for other inflammatory diseases that have limited treatment options.
Made from expanded mesenchymal stem cells (MSCs) from human adipose (fat) tissue, it contains the bioactive secretions of cells.
Progenza cells work by secreting cytokines, growth factors and exosomes that act in concert to reduce inflammation and pain and encourage accelerated healing and repair of damaged or diseased tissue.
The patent to be granted will provide Regeneus with the commercial rights to Progenza in up to 38 European member states, including the United Kingdom, Germany, France and Italy, until March 15, 2032.
Regeneus now has patents for Progenza in the world’s key markets for regenerative medicine, including Australia, New Zealand, Japan and the United States.
Its patents provide significant commercial protection for Progenza. Regeneus has more than 80 patents or patent applications across multiple patent families, providing its product pipeline with a significant competitive advantage.
CEO of Regeneus, John Martin, noted the significance of this development in Europe. “This is a major milestone for Progenza, enabling further protection of our commercial rights over the Progenza technology platform.
“Adding European patent protection to the product is a great development and further expands the potential market for our products.”
Earlier in 2018, Progenza was granted an Advanced Therapy Medicinal Product (ATMP) classification by the Committee for European Commission, recognising it as a novel regenerative therapy within the legal and regulatory framework for ATMPs in the European Union.
Regeneus continues to progress additional patent applications for Progenza in other key territories.
This content is produced by Star Investing in commercial partnership with Regeneus. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Don’t miss a thing, subscribe now